Literature DB >> 17051567

Transplantation for hepatocellular carcinoma: The Milan criteria and beyond.

Richard B Freeman1.   

Abstract

KEY CONCEPTS: 1. Liver transplantation offers excellent results for selected candidates with hepatocellular carcinoma (HCC). 2. Selection strategies have evolved but are mainly based on size and number of tumors, which are surrogates for vascular invasion. Newer techniques show promise for identifying patients at high risk for recurrence and selecting those with low risk, even though they may exceed currently established tumor size criteria. 3. Evaluation of the effectiveness of liver transplantation for HCC requires an intent-to-treat approach that must include an accounting of the dropout rate of patients while waiting. 4. Locoregional pretransplantation adjuvant treatments may have some role for downstaging and/or reducing the dropout rate before transplantation, but their posttransplantation effect on outcome remains undetermined. 5. Liver allocation for HCC candidates in the context of increasing HCC prevalence requires better and evidence-based prioritization policies. Copyright 2006 AASLD.

Entities:  

Mesh:

Year:  2006        PMID: 17051567     DOI: 10.1002/lt.20936

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  11 in total

1.  Transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Thuong G Van Ha
Journal:  Semin Intervent Radiol       Date:  2009-09       Impact factor: 1.513

2.  Combined dynamic contrast-enhanced liver MRI and MRA using interleaved variable density sampling.

Authors:  Mahdi Salmani Rahimi; Frank R Korosec; Kang Wang; James H Holmes; Utaroh Motosugi; Peter Bannas; Scott B Reeder
Journal:  Magn Reson Med       Date:  2014-03-17       Impact factor: 4.668

3.  Poorer survival in patients whose explanted hepatocellular carcinoma (HCC) exceeds Milan or UCSF Criteria. An analysis of liver transplantation in HCC in Australia and New Zealand.

Authors:  John W C Chen; Lilian Kow; Deborah J Verran; John L McCall; Stephen Munn; Glenda A Balderson; Jonathan W Fawcett; Paul J Gow; Robert M Jones; Gary P Jeffrey; Anthony K House; Simone I Strasser
Journal:  HPB (Oxford)       Date:  2009-02       Impact factor: 3.647

4.  Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence.

Authors:  Gudrun Zulehner; Mario Mikula; Doris Schneller; Franziska van Zijl; Heidemarie Huber; Wolfgang Sieghart; Bettina Grasl-Kraupp; Thomas Waldhör; Markus Peck-Radosavljevic; Hartmut Beug; Wolfgang Mikulits
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

5.  Liver transplantation.

Authors:  Deok-Bog Moon; Sung-Gyu Lee
Journal:  Gut Liver       Date:  2009-09-30       Impact factor: 4.519

6.  Rising costs and hospital admissions for hepatocellular carcinoma in Portugal (1993-2005).

Authors:  Rui Tato Marinho; José Giria; Miguel Carneiro Moura
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

7.  Total tumor volume is a better marker of tumor burden in hepatocellular carcinoma defined by the Milan criteria.

Authors:  Yun-Hsuan Lee; Cheng-Yuan Hsia; Chia-Yang Hsu; Yi-Hsiang Huang; Han-Chieh Lin; Teh-Ia Huo
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

8.  Electric Ablation with Irreversible Electroporation (IRE) in Vital Hepatic Structures and Follow-up Investigation.

Authors:  Xinhua Chen; Zhigang Ren; Tongyin Zhu; Xiongxin Zhang; Zhiyi Peng; Haiyang Xie; Lin Zhou; Shengyong Yin; Junhui Sun; Shusen Zheng
Journal:  Sci Rep       Date:  2015-11-09       Impact factor: 4.379

9.  Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach.

Authors:  Vincenzo Mazzaferro
Journal:  Hepatology       Date:  2016-02-26       Impact factor: 17.425

Review 10.  Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers.

Authors:  Lucia Cerrito; Brigida Eleonora Annicchiarico; Roberto Iezzi; Antonio Gasbarrini; Maurizio Pompili; Francesca Romana Ponziani
Journal:  World J Gastroenterol       Date:  2019-08-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.